We established the promising activity of two different highly specific PLK1 inhibitors, volasertib and onvansertib, in vitro, in traditional xenograft models, as well as in PDX models of platinum-sensitive and resistant SCLC. Here, PLK1 is linked to small cell lung carcinoma.